Oral administration of egg protein nanoparticles for the management of inflammatory bowel disease

被引:0
|
作者
Nguyen, Thuy-Vy [1 ,2 ]
Nguyen, Tien Tan [1 ,2 ]
Khuu, Chan-Quyen [1 ,2 ]
Nguyen, Thu-Ha Thi [1 ,2 ]
Vo, Toi Van [1 ,2 ]
Vong, Long Binh [1 ,2 ]
机构
[1] Int Univ, Sch Biomed Engn, Ho Chi Minh, Vietnam
[2] Vietnam Natl Univ Ho Chi Minh City, Ho Chi Minh, Vietnam
关键词
Egg protein nanoparticles; Inflammatory bowel disease; Oral drug delivery; Reactive oxygen species; Inflammation; AGGREGATION; MECHANISMS; GELATION;
D O I
10.1016/j.jddst.2024.106529
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder in the small and large intestines, characterized by immunological dysregulation, overproduction of free radicals, and imbalance of gut microorganisms. Egg white protein (EWP) is being considered a promising option for treating IBD due to its antioxidant, anti-inflammatory features, and intestinal bacteria regulation. In this study, egg protein nanoparticles (EPN) were prepared to improve the stability of EWP in the gastrointestinal (GI) tract and suppress oxidative stress and regulate immune response for treating IBD. The optimization of EPN synthesis involved the processes of cold gelation methods to obtain the suitable nanosize, surface charge, and stability of EPN under various pH conditions. The obtained EPN was approximately 100 nm with a narrow distribution and stable in gastric pH condition. EPN exhibited highly antioxidant and anti-inflammatory activities via ABTS scavenging assay and lipopolysaccharide-induced RAW 264.7 macrophage cell activation, respectively. In addition, oral administration of EPN showed a therapeutic efficacy in dextran sodium sulfate-induced colitis mice by effectively suppressing lipid peroxidation, pro-inflammatory cytokine and improving colon length, disease activity index, and colonic histology. Based on the obtained results in this study, EPN is a promising protein nanomedicine for treating IBD.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] INFLAMMATORY BOWEL-DISEASE AND ORAL CONTRACEPTION
    RITSCHARD, T
    FILIPPINI, L
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1986, 116 (18) : 594 - 597
  • [32] ORAL MANIFESTATIONS OF INFLAMMATORY BOWEL-DISEASE
    BASU, MK
    ASQUITH, P
    CLINICS IN GASTROENTEROLOGY, 1980, 9 (02): : 307 - 321
  • [33] The impact of inflammatory bowel disease on oral health
    Chandan, J. S.
    Thomas, T.
    BRITISH DENTAL JOURNAL, 2017, 222 (07) : 549 - 553
  • [34] Oral manifestations in patients with inflammatory bowel disease
    Shenkman, A
    Katz, J
    Meltzer, E
    Bar-Meir, S
    JOURNAL OF DENTAL RESEARCH, 1999, 78 (05) : 1098 - 1098
  • [35] Oral or IV Iron in Inflammatory Bowel Disease
    Auerbach, Michael
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (06): : 950 - 950
  • [36] The involvement of oral bacteria in inflammatory bowel disease
    Xiang, Bingjie
    Hu, Jun
    Zhang, Min
    Zhi, Min
    GASTROENTEROLOGY REPORT, 2024, 12
  • [37] Oral cyclosporin in refractory inflammatory bowel disease
    Taylor, ACF
    Elliott, R
    Connell, WR
    d'Apice, AJF
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1998, 28 (02): : 179 - 183
  • [38] The role of oral bacteria in inflammatory bowel disease
    Read, Emily
    Curtis, Michael A.
    Neves, Joana E.
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2021, 18 (10) : 731 - 742
  • [39] Oral manifestations of patients with inflammatory bowel disease
    Zervou, Flora
    ANNALS OF GASTROENTEROLOGY, 2005, 18 (01): : 95 - 95
  • [40] Innovations in Oral Therapies for Inflammatory Bowel Disease
    Ma, Christopher
    Battat, Robert
    Dulai, Parambir S.
    Parker, Claire E.
    Sandborn, William J.
    Feagan, Brian G.
    Jairath, Vipul
    DRUGS, 2019, 79 (12) : 1321 - 1335